Mounjaro 7.5 mg/0.5 mL pre-filled single-dose pen ( Japan Version) 2 dose per box

### **Mounjaro (Japan Version) – 7.5 mg/0.5 mL Pre-filled Single-dose Pen (2 Doses per Box)**

**Overview**:
Mounjaro, with the active ingredient **tirzepatide**, is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is used to treat adults with type 2 diabetes by improving blood sugar control. The **7.5 mg/0.5 mL pre-filled pen** is a single-use, subcutaneous injection, offering a precise and convenient dosage. In the Japan-specific version, the medication and pen design comply with local regulatory standards, including packaging and instructions.

**Dosage**:
– **7.5 mg/0.5 mL** is one of the available dose strengths of Mounjaro. This dosage is usually prescribed for patients who have adjusted from a lower initial dose (such as 5 mg) and are progressing toward more optimal glucose control.
– The **2 doses per box** configuration provides two pre-filled pens, each delivering one single dose of **7.5 mg** of tirzepatide.

**Key Features**:
– **Dual Mechanism**: Tirzepatide acts on both GIP and GLP-1 receptors, offering a unique mechanism compared to other GLP-1 receptor agonists. This dual action helps lower blood sugar levels by increasing insulin secretion, decreasing glucagon release, and slowing gastric emptying.
– **Once Weekly Injection**: Mounjaro is injected under the skin once a week, typically in the abdomen, thigh, or upper arm.
– **Pre-filled Pen**: The pen is designed for ease of use with a simple injection process, ideal for patients who need to self-administer the medication.

**Indications**:
– **Type 2 Diabetes**: Mounjaro is primarily prescribed to improve glycemic control in adults with type 2 diabetes, often in conjunction with other medications like metformin, sulfonylureas, or insulin.
– **Weight Reduction**: Patients may also experience weight loss as a beneficial secondary effect, which can be helpful in managing obesity-related complications.

**Usage Instructions**:
– **Frequency**: Mounjaro is administered once weekly, on the same day each week.
– **Administration**: The pre-filled pen delivers the full 7.5 mg dose in one injection, ensuring precise dosing.
– **Dose Adjustment**: If necessary, patients may start on a lower dose (e.g., 5 mg) and later increase to 7.5 mg based on their response and the doctor’s advice.

**Storage**:
– Store Mounjaro pens in a refrigerator (2°C to 8°C) before first use. Do not freeze the medication.
– After the first use, if a pen is not used immediately, it can be kept at room temperature (below 30°C) for up to 21 days.

**Packaging and Japan-Specific Information**:
– **2 Doses per Box**: The box contains two single-dose pens, providing two weeks of treatment.
– The Japan-specific version adheres to local guidelines for packaging and labeling, but the drug’s effectiveness and safety are consistent with global standards.

**Conclusion**:
Mounjaro (tirzepatide) 7.5 mg/0.5 mL pre-filled pen offers an effective and easy-to-use option for adults with type 2 diabetes. With its dual GIP and GLP-1 action, Mounjaro helps patients achieve better blood sugar control and may contribute to weight loss. The two-dose per box configuration ensures patients have a convenient supply for two weeks of treatment, simplifying diabetes management.